Bolsa PT - Gráfico de Análise Técnica Interactiva de Sepracor Inc. [SEPR]

Procure análises técnicas no nosso fórum aqui: Análises Técnicas

Nota: Os dados após 2009-10-29 são ainda temporários e poderão por isso ter o valor de Abertura errado até nova actualização...
Mudar para Gráfico Estático de Sepracor Inc.

Sepracor Inc. - [Ticker: SEPR]
Última Trade		Range 52 Semanas	[9,830 - 23,570]
Hora da Última Trade	N/A - N/A	Price-Target 1 Ano	N/A
Variação	()	Capitalização Bolsista	3
Bid / Ask	N/A	EPS	0,00
Abertura		PER	12,69%
Máximo		Pagamento Dividendo	N/A
Mínimo		Data Ex-Dividendo	2010-07-30
Fecho Anterior	22,850	Yield	N/A
Volume		Volume Médio (3m)	4.196.880
Nota: Os dados podem apresentar atraso de alguns minutos.

Notícias sobre Sepracor Inc. [SEPR]: (ordenadas por relevância)

DEALTALK-White knight could be elusive for Genzyme
Reuters
T) acquired Sepracor Inc for $2.6 billion. In 2008, Takeda Pharmaceutical Co (4502.T) acquired biotechnology company Millennium Pharmaceuticals for $8.9 ...

and more »

Name change in Sepracor's future
Boston Globe
Sepracor Inc., the Marlborough drug company perhaps best known for its Lunesta sleep aid, will be renamed Sunovion Pharmaceuticals Inc. in the United States ...
Sepracor to become Sunovion PharmaceuticalsWorcester Telegram
Sepracor Inc. to Become Sunovion Pharmaceuticals Inc.Genetic Engineering News (press release)
Sepracor to rename to SunovionMass High Tech
Worcester Business Journal
all 19 news articles »

United Bank Hires One Jane, Promotes Another
Worcester Business Journal
Previously, she was an accounts receivable accountant for Sepracor Inc. in Marlborough and, before that, she held various positions at OVO USA LLC in ...

Boston Globe

Another drug giant bringing jobs to Mass.
Boston Globe
Dainippon Sumitomo Pharma Co. acquired Sepracor Inc ,. the Marlborough company behind the Lunesta sleep medicine, for $2.6 billion in April. ...

and more »

Sepracor Reports Preliminary Results From A Second Phase III Study For OMNARIS ...
Medical News Today (press release)
Sepracor Inc. announced the preliminary results of a large-scale, 671-patient Phase III study of OMNARIS® (ciclesonide) HFA, an aerosol nasal formulation of ...

Business people
Worcester Telegram
Previously she worked as an accounts receivable accountant at Sepracor, Inc. in Marlboro and earlier held several positions at OVA USA, LLC in Hopkinton. ...

and more »

RocNow

Addressing conflicts of interests at university medical centers
RocNow
The website has a link to an ad that makes a pitch for Sepracor Inc.'s hand-held inhaler, Xopenex HFA, for relief of asthma symptoms. ...

and more »

Shawn Cross Appointed CEO of Burrill Merchant Banking Group
PR-USA.net (press release)
... Sons Inc. where he focused on growth oriented companies and completed a broad range of transactions for leading life sciences companies such as Sepracor ...

and more »

Shawn Cross Appointed CEO of Burrill Merchant Banking Group
PR Newswire (press release)
... Sons Inc. where he focused on growth oriented companies and completed a broad range of transactions for leading life sciences companies such as Sepracor ...

and more »

BNET	How Sepracor's Pointless Name Change May Minimize Internal Conflict BNET Sepracor, the company best known for its sleeping pill Lunesta, will change its name to ?Sunovion,? a move that will only ... and more »

Para mais notícias sobre Sepracor Inc. clique aqui:
Notícias de Sepracor Inc.